Production (Stage)
Evofem Biosciences, Inc.
EVFM
$0.01
$0.00044.17%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -76.55% | 46.81% | -12.05% | 69.24% | -37.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -76.55% | 46.81% | -12.05% | 69.24% | -37.98% |
| Cost of Revenue | -46.64% | 58.49% | -54.00% | -66.46% | -50.29% |
| Gross Profit | -83.56% | 43.94% | 12.53% | 1,955.15% | -34.15% |
| SG&A Expenses | -3.95% | 91.31% | -11.81% | -36.98% | -31.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -91.97% | -1.36% | -19.94% | -43.34% | -31.33% |
| Operating Income | 111.50% | 70.33% | 31.31% | 81.07% | 20.54% |
| Income Before Tax | 119.88% | -43.66% | -103.59% | 115.89% | -104.55% |
| Income Tax Expenses | -- | -- | -172.73% | 166.67% | -- |
| Earnings from Continuing Operations | 119.88% | -43.66% | -103.58% | 115.79% | -104.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 119.88% | -43.66% | -103.58% | 115.79% | -104.29% |
| EBIT | 111.50% | 70.33% | 31.31% | 81.07% | 20.54% |
| EBITDA | 119.63% | 79.75% | 39.32% | 80.71% | 15.06% |
| EPS Basic | 105.39% | 93.41% | -100.16% | 100.36% | 91.59% |
| Normalized Basic EPS | 104.46% | 84.20% | 98.95% | 100.37% | 89.72% |
| EPS Diluted | 100.13% | 95.86% | -125.20% | 99.98% | 91.36% |
| Normalized Diluted EPS | 100.08% | 84.20% | -80.00% | 100.01% | 89.72% |
| Average Basic Shares Outstanding | 263.39% | 807.32% | 2,176.86% | 4,136.35% | 2,353.35% |
| Average Diluted Shares Outstanding | 19,262.12% | 807.32% | -86.79% | 102,280.55% | 2,353.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |